STOCK TITAN

Director Joseph Molly awarded 19,358 RSUs at Lumexa Imaging (LMRI)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Lumexa Imaging Holdings, Inc. director Joseph Molly reported an equity compensation grant. He acquired 19,358 shares of common stock at a price of $0.00 per share as a grant or award, increasing his direct holdings to 46,385 shares.

The award is structured as restricted stock units, each representing the right to receive one share of common stock. These RSUs vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, as long as Molly continues to serve the company.

Positive

  • None.

Negative

  • None.
Insider Joseph Molly
Role null
Type Security Shares Price Value
Grant/Award Common Stock 19,358 $0.00 --
Holdings After Transaction: Common Stock — 46,385 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSU grant size 19,358 shares Grant/award of common stock on 2026-06-10
Grant price $0.00 per share Equity award, not market purchase
Post-transaction holdings 46,385 shares Total direct common stock after grant
restricted stock units ("RSUs") financial
"Represents restricted stock units ("RSUs"), each one of which represents the contingent right"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
contingent right financial
"each one of which represents the contingent right to receive one share"
vest financial
"The RSUs will vest on the earlier of the one-year anniversary of the grant date"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
annual meeting of the Issuer's stockholders financial
"the one-year anniversary of the grant date and the next annual meeting of the Issuer's stockholders"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Joseph Molly

(Last)(First)(Middle)
4200 SIX FORKS ROAD
SUITE 1000

(Street)
RALEIGH NORTH CAROLINA 27609

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Lumexa Imaging Holdings, Inc. [ LMRI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/10/2026A19,358(1)A$046,385D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents restricted stock units ("RSUs"), each one of which represents the contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of the one-year anniversary of the grant date and the next annual meeting of the Issuer's stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer.
Remarks:
Exhibit List: Exhibit 24 - Power of Attorney
/s/ Paul Gilbert, attorney-in-fact06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Lumexa Imaging Holdings (LMRI) report for Joseph Molly?

Lumexa Imaging Holdings reported that director Joseph Molly received a grant of 19,358 shares of common stock at $0.00 per share. The transaction is classified as a grant or award, not an open‑market purchase or sale.

How many Lumexa Imaging (LMRI) shares does Joseph Molly hold after this Form 4?

After the reported grant, Joseph Molly holds a total of 46,385 shares of Lumexa Imaging common stock directly. This reflects the addition of 19,358 awarded shares to his previous holdings, according to the Form 4 data.

What type of equity award did Lumexa Imaging (LMRI) grant to Joseph Molly?

The award consists of restricted stock units (RSUs), each representing the contingent right to receive one share of Lumexa Imaging common stock. These RSUs are part of the company’s equity compensation for the director, not a cash transaction.

When will Joseph Molly’s RSUs from Lumexa Imaging (LMRI) vest?

The RSUs will vest on the earlier of the one‑year anniversary of the grant date or the next annual stockholder meeting. Vesting is conditioned on Joseph Molly’s continued service with Lumexa Imaging until that time.

Is the Lumexa Imaging (LMRI) Form 4 transaction a market buy or sell?

No. The Form 4 classifies the transaction as a grant, award, or other acquisition of 19,358 shares at $0.00 per share. It reflects equity compensation to the director, not an open‑market purchase or sale.